These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 35181259)
1. Pharmacological treatment with lipid-lowering agents after molecular identification of familial hypercholesterolemia: results from the Hipercol Brasil cohort. Silva PRS; Jannes CE; Oliveira TGM; Krieger JE; Santos RD; Pereira AC J Clin Lipidol; 2022; 16(2):198-207. PubMed ID: 35181259 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil. Silva PRS; Jannes CE; Oliveira TGM; Miname MH; Rocha VZ; Chacra AP; Gurgel MHC; Montenegro RM; Rodrigues Sobrinho CRM; Bello Moreira AS; Assad MHV; Pinto MRC; Tada MT; Santos RD; Pereira AC; Krieger JE Atherosclerosis; 2017 Aug; 263():257-262. PubMed ID: 28689098 [TBL] [Abstract][Full Text] [Related]
3. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694 [TBL] [Abstract][Full Text] [Related]
4. Health related quality of life in individuals at high risk for familial hypercholesterolemia undergoing genetic cascade screening in Brazil. Souto AC; Miname MH; Fukushima J; Jannes CE; Krieger JE; Hagger M; Pereira AC; Santos RD Atherosclerosis; 2018 Oct; 277():464-469. PubMed ID: 30270086 [TBL] [Abstract][Full Text] [Related]
5. Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia. Silva PR; Jannes CE; Marsiglia JD; Krieger JE; Santos RD; Pereira AC Atherosclerosis; 2016 Jul; 250():144-50. PubMed ID: 27214396 [TBL] [Abstract][Full Text] [Related]
6. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark. Jensen HK Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167 [TBL] [Abstract][Full Text] [Related]
7. Latvian registry of familial hypercholesterolemia: The first report of three-year results. Latkovskis G; Saripo V; Gilis D; Nesterovics G; Upena-Roze A; Erglis A Atherosclerosis; 2018 Oct; 277():347-354. PubMed ID: 30270070 [TBL] [Abstract][Full Text] [Related]
8. Cascade screening and treatment of children with familial hypercholesterolemia in Turkey. Kose E; Kose M; Ozturk SI; Ozcan E; Onay H; Ozkan B J Pediatr Endocrinol Metab; 2020 Aug; 33(10):1251-1256. PubMed ID: 32829317 [TBL] [Abstract][Full Text] [Related]
9. Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk. Lee S; Akioyamen LE; Aljenedil S; Rivière JB; Ruel I; Genest J Eur J Prev Cardiol; 2019 Aug; 26(12):1262-1270. PubMed ID: 30755017 [TBL] [Abstract][Full Text] [Related]
10. [Screening for familial hypercholesterolemia from low-density lipoprotein cholesterol levels at admission in the coronary care unit]. Chemaly P; Nallet O; Delarche N; Legagneur C; Boulestreau R; Reibel I; Palette C; Grenier A; Courtade H; Beaune G; Belle L; Georges JL Ann Cardiol Angeiol (Paris); 2018 Nov; 67(5):300-309. PubMed ID: 30290906 [TBL] [Abstract][Full Text] [Related]
11. Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force. Lozano P; Henrikson NB; Dunn J; Morrison CC; Nguyen M; Blasi PR; Anderson ML; Whitlock EP JAMA; 2016 Aug; 316(6):645-55. PubMed ID: 27532919 [TBL] [Abstract][Full Text] [Related]
12. Cascade screening and genetic diagnosis of familial hypercholesterolemia in clusters of the Southeastern region from Brazil. de Paiva Silvino JP; Jannes CE; Tada MT; Lima IR; Silva IFO; Pereira AC; Gomes KB Mol Biol Rep; 2020 Dec; 47(12):9279-9288. PubMed ID: 33231818 [TBL] [Abstract][Full Text] [Related]
13. Efficiency and problems of statin therapy in patients with heterozygous familial hypercholesterolemia. Korneva V; Kuznetsova T; Julius U Atheroscler Suppl; 2019 Dec; 40():79-87. PubMed ID: 31818452 [TBL] [Abstract][Full Text] [Related]
14. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. Huijgen R; Kindt I; Verhoeven SB; Sijbrands EJ; Vissers MN; Kastelein JJ; Hutten BA PLoS One; 2010 Feb; 5(2):e9220. PubMed ID: 20169164 [TBL] [Abstract][Full Text] [Related]
15. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia. Santos PC; Morgan AC; Jannes CE; Turolla L; Krieger JE; Santos RD; Pereira AC Atherosclerosis; 2014 Mar; 233(1):206-10. PubMed ID: 24529145 [TBL] [Abstract][Full Text] [Related]